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Abstract: Age-related macular degeneration (AMD) is the leading cause of vision loss in 
the industrialized world. In the last few decades, the mainstay of treatment for choroidal 
neovascularization (CNV) due to AMD has been thermal laser photocoagulation. In the last 
decade, photodynamic therapy with verteporﬁ  n extended treatment for more patients. While 
both of these treatments have prevented further vision loss in a subset of patients, improvement 
in visual acuity is rare. Anti-vascular endothelial growth factor A (VEGF) therapy has 
revolutionized the treatment of AMD-related CNV. Pegaptanib, an anti-VEGF aptamer prevents 
vision loss in CNV, although the performance is similar to that of photodynamic therapy. 
Ranibizumab, an antibody fragment and bevacizumab, a full-length humanized monoclonal 
antibody against VEGF have both shown promising results with improvements in visual acuity 
with either agent. VEGF trap, a modiﬁ  ed soluble VEGF receptor analogue, binds VEGF more 
tightly than all other anti-VEGF agents and has also shown promising results in early trials. 
Other treatment strategies to decrease the effect of VEGF have used small interfering ribonucleic 
acid (RNA) to inhibit VEGF production and VEGF receptor production. Steroids, including 
anecortave acetate in the treatment and prevention of CNV, have shown promise in controlled 
trials. Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of 
VEGF, and have been effective in the treatment of CNV in early studies. Squalamine lactate 
inhibits plasma membrane ion channels with downstream effects on VEGF, and has shown 
promising results with systemic administration. Other growth factors, including pigment 
epithelium-derived growth factor that has been administered via an adenoviral vector has 
shown promising initial results. In some patients ciliary neurotrophic factor is currently 
being studied for the inhibition of progression of geographic atrophy. Combination therapy 
has been investigated, and may prove to be more effective in the management of AMD-
associated CNV. Ongoing and future studies will be crucial for optimizing the treatment of 
patients with AMD.
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Introduction
In 2002, the World Health Organization estimated there were 161.2 million visually 
impaired people in the world; 14 million (8.7%) of whom had age-related macular 
degeneration (AMD) (World Health Organization 2007). In industrialized countries, 
AMD is the leading cause of adult vision loss. Choroidal neovascularization (CNV) is 
responsible for approximately 90% of the cases of severe vision loss due to AMD, and 
geographic atrophy (GA) is responsible for the remaining 10% (Eye Diseases Prevalence 
Research Group 2004; Klein et al 2006). In 2004, the estimated prevalence of AMD-
related CNV in industrialized countries was 1.02% for people over the age of 40 years, 
and 8.18% for people over the age of 80 years (Eye Diseases Prevalence Research 
Group 2004). The magnitude of this problem has driven enormous research efforts Clinical Ophthalmology 2008:2(2) 378
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regarding the prevention and treatment of AMD-related CNV 
and GA. Until recently, laser photothermal and photodynamic 
therapy have been the only treatments that have demonstrated 
beneﬁ  t in large controlled clinical trials for the management 
of AMD-related CNV. For some patients with dry AMD, 
the use of oral micronutrient supplementation has reduced 
the rate of disease progression. Better understanding of the 
pathophysiologic mechanisms of AMD-related CNV and GA 
has allowed for the recent emergence of pharmacotherapy as 
a more targeted treatment approach toward both conditions. 
This article reviews the current level of understanding 
regarding several of these new treatments for AMD-related 
CNV and GA (Table 1).
Dry age-related macular 
degeneration and geographic 
atrophy
Dry AMD includes the spectrum of ﬁ  ndings from minimal 
drusen through geographic atrophy (GA), so long as no 
evidence of neovascularization is present. For patients with 
Table 1 Current status of therapy for dry and wet age-related macular degenerationa
Therapeutic modality Supporting studies 
[references in text]
Level of evidence Notes
Antioxidant micronutrient 
supplementation
AREDSb Phase III study Odds ratio 0.73 for  3 lines vision loss 
at 5 years.
Argon laser photocoagulation MPSc Phase III studies 45% risk reduction of  6 lines vision 
loss at 3 years
Photodynamic therapy with 
verteporﬁ  n
TAP,d VIPe FDA approved 42% risk reduction of  3 lines vision 
loss at 2 years
Pegaptanib VISIONf FDA approved 33% risk reduction of  3 lines vision 
loss at 1 year
Ranibizumab ANCHOR,g MARINA,h PIER,i 
PrONTOj
FDA approved Gain of 6.6 letters at 2 years 
Bevacizumab Case seriesk,l,m,n,o CATT (phase III) in planning stage Gain of 15–30 lettersp
VEGF trap CLEAR IT-1q Phase I; CLEAR-AMD (phase II) in 
enrolment
Gain of 4.8 letters at 6 weeks
Bevasiranib CAREr Phase II Loss of 4.9–6.9 letters at 12 weeks
Sirna-027 Sirnas Phase I; phase II in enrolment Reasonable side-effect proﬁ  le
Vatalanib ADVANCEt Phase I; phase I/II in enrolment Reasonable side-effect proﬁ  le
AdPEDF.11 GenVecu Phase I; phase Ib in data collection Reasonable side-effect proﬁ  le
Squalamine lactate Squalaminev Phase I/II; Phase III in enrolment Gain of  3 lines in 26%
Anecortave acetate C-01-99w Phase III No beneﬁ  t over verteporﬁ  n
aFor details and abbreviations of study names, please see manuscript text.
bAge-Related Eye Disease Study Research Group 2001.
cMacular Photocoagulation Study Group 1986.
dTreatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group 2001.
eTreatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group 2003.
fKeyt 1996.
gHeier, Boyer, et al 2006.
hRosenfeld 2006a.
iBrown 2006.
jSchmidt-Erfurth 2007.
kHurwitz 2004.
lMoshfeghi 2006.
mSpaide 2006.
nRich 2006.
oAvery 2006.
pNo published series of bevacizumab use employs ETDRS protocol visual acuity measurements, and the stated gain in vision likely overestimates that which might be 
obtained by more rigorous vision testing methods.
qNguyen 2006.
rNguyen 2006.
sTolentino 2006.
tJoondeph 2006.
uImai 2005.
vCiulla 2003 (Genaera has abandoned this product and is no longer in clinical development).
wKaiser 2007.Clinical Ophthalmology 2008:2(2) 379
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mild disease, such as extensive small drusen ( 63 μm in 
diameter) or nonextensive intermediate size drusen ( 63 μm, 
 125 μm), the risk of losing vision or developing CNV or 
GA over 5 years is relatively low, at 1.3% (Age-Related 
Eye Disease Study Research Group 2001). At the other end 
of the dry spectrum, GA occurs when areas of the retinal 
pigment epithelium (RPE) gradually disappear resulting in 
growing and coalescing areas of total RPE atrophy. Absence 
of the RPE leads to fallout of underlying choriocapillaris and 
overlying photoreceptors and affected areas correspond to 
scotomata (Spraul et al 1996).
Antioxidant therapy
The only therapy with proven beneﬁ  t in patients with dry 
AMD is a combination of oral antioxidant supplements, 
containing vitamin C (500 mg) and vitamin E (400 IU), 
beta-carotene (15 mg, often labelled as equivalent to 25,000 
IU of vitamin A); and zinc as zinc oxide (80 mg) and copper 
as cupric oxide (2 mg) (Age-Related Eye Disease Study 
Research Group 2001). This study found that patients 
with the intermediate (extensive intermediate size drusen 
or at least 1 large size druse ( 125 μm)) or advanced 
(CNV or central GA in 1 eye) stages of AMD experience 
a statistically signiﬁ  cant reduction in the 5-year rate of 
moderate vision loss, and progression to CNV or central 
GA. Therefore, the AREDS formula is recommended 
for those patients with the intermediate stage of AMD or 
worse, unless there are contraindications to the use of these 
oral micronutrient supplements. Copper was added to the 
AREDS formulations containing zinc to prevent copper 
deﬁ  ciency anaemia, a condition associated with high levels 
of zinc intake.
Because the effects of high-dose beta-carotene are 
harmful in some patient populations, including smokers 
(Alpha-Tocopherol, Beta Carotene Cancer Prevention Study 
Group 1994), and the AREDS formula did not include other 
potentially beneﬁ  cial micronutrients; the AREDS Research 
Group is currently enrolling a second trial (AREDS2) to 
investigate alternatives to the original AREDS formula. 
AREDS2 will address the role of omega-3 fatty acids and 
lutein as well as decreased dosages of beta-carotene in 
patients with intermediate or advanced AMD.
Although oral antioxidant supplementation helps prevent 
vision loss, local delivery of antioxidants is an area of current 
interest because a small but signiﬁ  cant increase in the rate 
of hospitalization for urinary tract infections, among other 
conditions, has been reported (Age-Related Eye Disease 
Study Research Group 2001). The National Eye Institute is 
sponsoring a phase II trial of an antioxidant OT-551 (Othera 
Pharmaceuticals, Inc., Exton, PA), a low molecular weight 
compound metabolized to TP-H, which is a potent free-
radical scavenger (National Institute of Health 2007). The 
study drug is administered topically as a drop three times 
daily in patients with bilateral GA, the progression of which 
will be assessed over a 2-year period.
Anecortave acetate
Anecortave acetate (Retaane®, Alcon Research, Ltd., Fort 
Worth, TX, USA), is an angiostatic steroid that does not 
exhibit glucocorticoid receptor-mediated activity. Its use 
in ocular disease is attractive because of its dosing and 
delivery: 15 mg delivered as a posterior juxtascleral depot 
every 6 months. Because of its favourable dosing schedule 
and delivery and low risk proﬁ  le, anecortave acetate is being 
studied in the Anecortave Acetate Risk Reduction Trial 
(AART) for the prevention of CNV in patients with eyes at 
high risk of converting from non-neovascular to neovascular 
AMD. This study targets patients with bilateral large size 
drusen and pigment changes who have a particularly high 
5-year risk of progression to advanced AMD (47%) based on 
the AMD simpliﬁ  ed severity scale (Ferris et al 2005).
Age-related macular degeneration-
related choroidal neovascularization
In choroidal neovascularization anomalous choroidal 
vessels grow under or through the RPE (Green et al 
1993). Although speciﬁ  c stimuli for CNV growth remain 
unknown, it generally occurs in the presence of soft drusen, 
breaks in Bruch membrane, and a pro-inﬂ  ammatory and 
pro-angiogenic milieu, characterized by elevated levels of 
vascular endothelial growth factor A (VEGF) or platelet-
derived growth factor (PDGF) (Ambati et al 2003).
Choroidal neovascularization has various patterns and 
conﬁ  gurations of proliferation that have been described 
based on its appearance with ﬂ  uorescein angiography (FA). 
This highly useful diagnostic test allows one to determine 
the pattern, boundaries, composition and location of 
the neovascular lesions with respect to the centre of the 
fovea. These patterns of ﬂ  uorescence have been shown 
to be reliable and reproducible in multi-centre clinical 
trials and in practice (Macular Photocoagulation Study 
Group 1982; Macular Photocoagulation Study Group 
1986; Macular Photocoagulation Study Group 1991; 
Macular Photocoagulation Study Group 1993; Macular 
Photocoagulation Study Group 1994; Treatment of Age-
related Macular Degeneration with Photodynamic Therapy Clinical Ophthalmology 2008:2(2) 380
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(TAP) Study Group 2001; Treatment of Age-related 
Macular Degeneration with Photodynamic Therapy (TAP) 
Study Group 2003). Classic CNV refers to a discrete, well-
demarcated focal area of hyperﬂ  uorescence seen during 
the early images of the FA that increases in the intensity of 
ﬂ  uorescence as the FA images progress in the later phases. 
The hyperﬂ  uorescence not only increases in intensity but also 
extends beyond the boundary of the initial lesion seen in the 
early FA images. Occult CNV refers angiographic patterns 
lacking the features of classic CNV and is characterized by 
stippled or speckled hyperﬂ  uorescence that is frequently 
seen in the mid to later FA images. Occult CNV has been 
divided in to two types, ﬁ  brovascular pigment epithelial 
detachment(FVPED) and late leakage of an undetermined 
source(LLUS). In FVPED, the lesion has ophthalmoscopic 
or photographically appreciable thickness or elevation when 
viewed stereoscopically. The stippled hyperﬂ  uorescence 
may become well deﬁ  ned in the later FA images. In LLUS, 
the lesion is not elevated when viewed stereoscopically. 
The choroidal based stippled or speckled hyperﬂ  uorescence 
appears in the mid to late FA images and have no classic or 
FVPED angiographic qualities. CNV are also described by 
location. In subfoveal CNV, any component of the lesion 
resides underneath the geometric centre of the fovea. In 
extrafoveal CNV the edge of the lesion is no closer that 200 
micrometers from the foveal centre. Those lesions whose 
edges reside within 1–199 micrometers from the foveal 
centre are juxtafoveal (Macular Photocoagulation Study 
Group 1991). When at least 50% of a choroidal neovascular 
lesion’s composition is of a particular pattern, the qualiﬁ  er 
predominantly is applied, as in predominantly classic, 
predominantly occult, or predominantly hemorrhagic. When 
less that 50% of a choroidal neovascular lesion’s composition 
is of a particular pattern, the term minimally is applied, as 
in minimally classic (Treatment of Age-related Macular 
Degeneration with Photodynamic Therapy (TAP) Study 
Group 2003).
Natural history data have indicated that 62% of eyes 
with predominantly classic subfoveal CNV lose 3 or more 
lines of visual acuity at 2 years with 30%–48% losing 6 or 
more lines (Macular Photocoagulation Study Group 1993). 
The prognosis for eyes with CNV that does not involve the 
centre of the fovea is slightly worse, with 49%–62% losing 
6 or more lines at 3 years, likely due to better visual acuity 
at baseline (Macular Photocoagulation Study Group 1986; 
Macular Photocoagulation Study Group 1994). Visual 
acuity outcomes are worse for eyes with larger lesions but 
are slightly better for eyes with occult angiographic patterns 
(Treatment of Age-related Macular Degeneration with 
Photodynamic Therapy (TAP) Study Group 2003). Since 
poor visual outcomes occur without treatment, the prompt 
administration of safe and effective therapy is paramount in 
the management of CNV due to AMD.
Thermal laser photocoagulation
The Macular Photocoagulation Study (MPS) compared 
focal thermal laser photocoagulation of choroidal 
neovascularization to observation for CNV in AMD patients 
and consisted of multiple randomized clinical trials. Within 
1 year of treatment, 25% of eyes with extrafoveal CNV 
due to AMD had lost fewer than 6 lines of vision with laser 
compared to 60% of eyes in the observation group (Macular 
Photocoagulation Study Group 1982), with a difference that 
persisted through 3 years (Macular Photocoagulation Study 
Group 1986). Two years after treatment, 21% of eyes with 
subfoveal CNV lost 6 or more lines of vision compared to 38% 
of eyes in the observation group (Macular Photocoagulation 
Study Group 1991). Unfortunately, eyes lasered for subfoveal 
CNV initially experience a marked drop in vision due 
to damage to the macular centre from photocoagulation. 
This undesirable effect and the advent of newer treatment 
options, make thermal laser photocoagulation a seldom-used 
treatment for patients with subfoveal CNV. Today, MPS-
style thermal laser photocoagulation for extrafoveal CNV 
is still considered an effective method of treatment and is 
used in selected cases.
Photodynamic therapy with verteporﬁ  n
Photodynamic therapy (PDT) involves an intravenous 
infusion of a photosensitizing agent that selectively binds 
to the increased number of lipoprotein receptors on the 
endothelium of abnormal vessels including CNV. The 
photosensitizing agent is then activated with laser light, 
usually in the far-red spectrum where light transmission 
through tissue and blood is higher. Activation of the 
photosensitizer, which is usually structurally related to 
porphyrin, results in free-radical formation, endothelial 
damage, and clotting cascade activation with thrombosis of 
the affected, abnormal vasculature. Verteporﬁ  n® (Visudyne, 
Novartis AG, Basel Switzerland) was the ﬁ  rst photosensitizer 
approved for use in exudative AMD. It is administered at a 
dose of 6 mg/m2 and is activated by 689–691 nanometer laser 
light. The Treatment of Age-related Macular Degeneration 
with Photodynamic Therapy (TAP) study demonstrated a 
particular treatment beneﬁ  t for patients with predominantly 
classic subfoveal CNV. At 2 years, PDT with verteporﬁ  n Clinical Ophthalmology 2008:2(2) 381
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prevented loss of 3 or more lines of vision in 67% of these 
patients, compared to 39% of controls (Treatment of Age-
related Macular Degeneration with Photodynamic Therapy 
(TAP) Study Group 2001). However, 33% of patients still lost 
3 or more lines of vision over 2 years. In addition, it has been 
observed that PDT with verteporﬁ  n initiates an inﬂ  ammatory 
response and up regulates VEGF and other growth factors 
that contribute to recurrence of CNV (Schmidt-Erfurth 
et al 2003). As such PDT with verteporﬁ  n is not currently 
preferred as monotherapy for the management of AMD-
related CNV.
VEGF-binding agents
The vascular endothelial growth factor family consists of 
seven members (vascular endothelial growth factors A 
through F, and placental growth factor), which are secreted 
polypeptides that share common structural domains but have 
different biological and physical properties (Ferrara 2004). 
VEGF plays a role in normal and pathologic angiogenesis 
and has at least six known isoforms which are formed through 
alternative splicing and are named based on their number 
of amino acids: 121, 145, 165, 183, 189, and 206 (Ferrara 
2004). VEGF165 is a potently pro-angiogenic molecule 
that has been shown to effect retinal vascular proliferation 
and increased vascular permeability in the eye (Adamis 
et al 2005). Neovascular membranes in patients with AMD 
contain both isoforms VEGF165 and VEGF121 (Rakic et al 
2003). The 165 isoform can be cleaved by plasmin to form 
the 110 amino acid fragment (VEGF110) that retains biologic 
activity (Keyt et al 1996). Animal models have also suggested 
that VEGF165 plays a role in inﬂ  ammation, induction of 
leukocyte recruitment, and neuroprotection against ischemic 
injury (Nishijima et al 2007). This suggests that VEGF 
blockade may have both deleterious and salubrious effects in 
eyes with vascular disease. VEGF modulation has therefore 
been a target of many CNV treatments (Figure 1).
Pegaptanib
The ﬁ  rst available anti-VEGF treatment for use in the eye 
was pegaptanib (Macugen®, Eyetech Pharmaceuticals, Inc., 
New York, NY, USA), an aptamer that targets VEGF165. 
In the VEGF Inhibition Study in Ocular Neovascularization 
Clinical Trial (VISION), pegaptanib was shown to be safe 
and effective in preventing vision loss in patients with AMD-
related CNV for over 2 years when compared to controls 
(Gragoudas et al 2004). However, visual decline occurred 
over time in a pattern similar to that seen with PDT with 
verteporﬁ  n. This persistent loss of vision despite treatment 
with pegaptanib may be due to its selective binding to 
VEGF165 only, leaving all other isoforms uninhibited and 
available to stimulate neovascularization. Furthermore, its 
dosing of intravitreal injections every 6 weeks, compared 
to the less-invasive quarterly dosing schedule of PDT with 
verteporﬁ  n gave pegaptanib treatment of neovascular AMD 
no competitive advantage.
VEGF antibodies and antibody fragments
Both bevacizumab (Avastin®, Genentech, Inc., South San 
Francisco, CA, USA), a full-length humanized antibody 
against VEGF, and ranibizumab (Lucentis®, Genentech, Inc.), 
a humanized antigen-binding fragment against VEGF, are 
able to bind and inhibit all isoforms of VEGF (Ferrara et al 
2004). Although ranibizumab has one binding site for VEGF 
compared to bevacizumab’s two, ranibizumab has been afﬁ  nity 
matured, exhibiting 3- to 6-fold higher afﬁ  nity for VEGF than 
bevacizumab (Presta et al 1997; Chen et al 1999).
Ranibizumab is the ﬁ  rst therapy for neovascular AMD 
to result in a significant improvement in visual acuity 
(Heier et al 2006). Two phase III studies of the use of 
monthly intravitreal injections of ranibizumab, MARINA 
and ANCHOR have been completed (Brown et al 2006; 
Rosenfeld et al 2006a). MARINA evaluated 716 patients with 
minimally classic or occult neovascular AMD. At 2 years, 
MARINA demonstrated a mean gain of 5.4 letters (0.3 mg 
group) to 6.6 letters (0.5 mg group) for patients treated with 
monthly ranibizumab injections compared to a mean loss of 
14.9 letters for patients undergoing monthly sham injections 
(Rosenfeld et al 2006a). ANCHOR evaluated 423 patients 
with predominantly classic neovascular AMD. At 1 year, 
ANCHOR demonstrated a mean gain of 8.5 letters (0.3 mg 
group) to 11.3 letters (0.5 mg group) for patients treated with 
monthly ranibizumab injections compared to a mean loss of 
9.5 letters for patients treated with verteporﬁ  n every 3 months 
(Brown et al 2006). The 0.5 mg dose prevented 3 lines 
of vision loss in 90% (MARINA) to 96.4% (ANCHOR) 
compared to sham (52.9%) or verteporﬁ  n (64.3%). The 
0.5 mg dose resulted in 3 or more lines of vision gain in 
33.8% (MARINA) to 40.3% (ANCHOR) compared to 
sham (5.0%) or verteporﬁ  n (5.6%). All comparisons were 
statistically signiﬁ  cant (p   0.001). Serious adverse events for 
patients treated with ranibizumab included endophthalmitis 
(1% (MARINA) to 1.4% (ANCHOR)) and uveitis (0.7% 
(ANCHOR) to 1.3% (MARINA)). Arterial thromboembolic 
events occurred in 3.8% of the sham group compared to 4.6% 
in each of the ranibizumab groups (MARINA), and 2.1% of 
the verteporﬁ  n group compared to 2.2% (0.3 mg group) and Clinical Ophthalmology 2008:2(2) 382
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4.3% (0.5% group) for the ranibizumab groups (ANCHOR). 
Although some might consider these data to demonstrate a 
high level of safety, neither study was powered to evaluate 
safety concerns. In fact, at a 6-month interim evaluation, 
the SAILOR study, a phase IV evaluation of the safety and 
efﬁ  cacy of 0.3 mg and 0.5 mg doses of as-needed ranibizumab 
reported a statistically signiﬁ  cant increase in the rate of stroke 
(0.3% compared to 1.2%) with the higher (commercially 
available) dose whereas for arterial thromboembolic events 
of myocardial infarction or vascular death, the differences 
between the doses were not statistically signiﬁ  cant [personal 
communication, Genentech, Inc., January 24, 2007]
The burden of monthly injections of ranibizumab coupled 
with the appreciable risk of adverse events prompted the PIER 
and PrONTO studies (Rosenfeld 2006b; Schmidt-Erfurth 
2007). Each study used less frequent dosing than ANCHOR 
and MARINA, with PIER using a ﬁ  xed dosing schedule and 
PrONTO using an “as needed” schedule. PIER was a phase 
IIIb randomized, double-masked, sham-controlled study of 
184 subjects who received monthly injections of ranibizumab 
or sham for 3 months, followed by quarterly injections. 
At 12 months, the sham group lost 16 letters, whereas the 
ranibizumab group initially gained one line but lost 0.2 letters 
at 12 months (Schmidt-Erfurth 2007). Although the study 
did not include a monthly injection of ranibizumab arm, 
comparison to ANCHOR and MARINA data would suggest 
inferiority with the PIER dosing schedule.
The PrONTO study was an open label study of 40 eyes 
treated with 3 consecutive monthly injections of 0.5 mg 
ranibizumab followed by further injections based on loss of 
5 letters visual acuity or increase of 100 μm of central retinal 
thickness. Through 1 year, patients required an average of 
VEGF
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VEGF mRNA
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Ranibizumab
Bevacizumab
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Ion transporters
Vatalanib
Figure 1 Mechanisms of inhibition of vascular endothelial growth factor-A (VEGF). Pegaptanib, ranibizumab, bevacizumab, and VEGF trap bind and sequester VEGF, 
preventing it from binding and activating VEGF receptor. Inhibitors of VEGF receptor tyrosine kinases prevent transduction of the VEGF binding signal. Small interfering RNA 
molecules prevent translation of VEGF (bevasiranib) or VEGF receptor-1 (Sirna-027). Squalamine interferes with the function of various ion transport channels, the activity 
of which is required for angiogenesis. Double dotted lines represent cellular plasma membranes and the single dotted line represents nuclear membrane.Clinical Ophthalmology 2008:2(2) 383
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5.6 injections, 35% gained 3 or more lines, and 95% lost 
fewer than 3 lines of vision (Rosenfeld 2006b). Although 
the criteria for re-treatment have not been systematically 
evaluated, and some clinicians would support treating based 
on other factors than those evaluated in PrONTO, decreasing 
the number of required injections would substantially reduce 
the burden of AMD treatment on patients.
Bevacizumab is a full-length antibody with similar 
properties to ranibizumab, and is approved for systemic use 
in some solid tumours and is therefore available for off-label 
use in the treatment of AMD-related CNV (Hurwitz 2004). 
An open-label uncontrolled clinical study of intravenous 
infusion of bevacizumab (5 mg/kg) at baseline with 1–2 
repeated doses at 2-week intervals in 18 patients reported a 
statistically signiﬁ  cant median gain of 14 letters and decrease 
of OCT thickness from 379 to 255 μm (Moshfeghi et al 
2006). The only signiﬁ  cant ocular or systemic adverse event 
was hypertension, which occurred or worsened in 10 patients 
and was readily treated with oral medications.
Concerns about thromboembolic events with use of 
intravenous bevacizumab in the treatment of cancer prompted 
investigators to use bevacizumab intravitreally. Multiple 
retrospective studies have reported on the use of 1.25 mg 
doses of intravitreal bevacizumab, citing three or more lines 
of vision improvement in 38.3% (Spaide et al 2006) to 44% 
(Rich et al 2006) of treated patients and median gain of 
15 letters (Rich et al 2006) to 20 letters (Avery et al 2006) 
at 8–12 weeks. One prospective study of monthly injections 
of 2.50 mg bevacizumab reported median gain of 6 lines of 
vision and normalization of central retinal thickness from 
350 to 211 μm using optical coherence tomography (OCT) 
(Bashshur et al 2006). Although, the OCT data in these 
reports are compelling; the visual acuity data did not employ 
Early Treatment for Diabetic Retinopathy Study (ETDRS) 
protocol visual acuities and as such may not accurately reﬂ  ect 
visual acuity improvement in these patient series.
In each of the reports on intravitreal bevacizumab, negligible 
adverse events were noted. This was an important ﬁ  nding since 
numerous concerns were raised with the intravitreal injections 
of humanized antibody such as the inciting of intraocular 
inﬂ  ammation or the promotion of systemic thromboembolic 
side effects. Acknowledging the bias inherent in a survey based 
on self-reporting, an internet survey of adverse events of 3810 
intravitreal injections in 3034 patients following intravitreal 
bevacizumab injections reported low rates of treatment-related 
and drug-related adverse events, citing rates of 0.03% for 
endophthalmitis and 0.1% for all forms of cerebrovascular 
events (Fung et al 2006). Concerns regarding the durability 
of compounded bevacizumab have been put to rest by in vitro 
studies of VEGF binding following refrigeration or freezing 
for up to 6 months (Bakri et al 2006).
At this time, efﬁ  cacy data are superior for ranibizumab 
than bevacizumab, and each has demonstrated reasonable 
safety, with the exception of concern for increased rates of 
stroke demonstrated by SAILOR. In an effort to clarify these 
issues, the National Eye Institute has agreed to sponsor a 
multi-centre trial comparing ranibizumab to bevacizumab 
with ﬁ  xed monthly versus variable dosing schedules. The 
Comparison of Age-related Macular Degeneration Treatment 
Trial (CATT) is scheduled to begin enrolling patients in 
the fall of 2007. Until this question can be answered by the 
CATT, we will be forced to treat patients with medication 
availability and ﬁ  nancial feasibility issues in mind. The 
September, 2006 Preferences and Trends (PAT) survey, 
administered by the American Society of Retina Specialists 
(ASRS), in which the response rate was 23.57% of 1667 
ASRS members demonstrated that 34.70%–41.75% would 
recommend bevacizumab for the treatment of subfoveal 
CNV and 33.42%–41.75% would recommend ranibizumab. 
(American Society of Retina Specialists 2007) A follow-up 
mini survey of the same population of retina specialists 
(n = 276 responders) speciﬁ  ed whether the hypothetical 
patient was covered by Medicare with or without secondary 
insurance coverage, without which patients in the United 
States would be responsible for 20% of the medication bill, 
or approximately US$400 per injection (American Society 
of Retina Specialists 2007). In this survey, 53.11% would 
recommend bevacizumab for patients with secondary 
insurance, increasing to 77.01% for patients without 
secondary insurance.
VEGF trap
The VEGF trap (Regeneron Pharmaceuticals, Inc., Tarrytown, 
NY, USA) is a fusion protein of portions of VEGF receptor 
1 and 2 and the Fc region of human IgG which binds all 
VEGF isoforms and does so more tightly than other available 
VEGF binding agents. The Clinical Evaluation of Anti-
angiogenesis in the Retina (CLEAR) study was a randomized, 
double-masked, ascending dose, placebo-controlled phase 
I trial of 18 patients with neovascular AMD who received 
either placebo or 1 of 3 systemic doses of intravenous VEGF 
trap (0.3, 1.0, and 3.0 mg/kg) (Nguyen et al 2006). The study 
found a dose-dependent increase in systemic blood pressure, 
which was clinically signiﬁ  cant above the 1.0 mg/kg dose 
and further studies of systemic VEGF trap were halted. 
CLEAR IT-1 was a phase I dose escalation study of a single Clinical Ophthalmology 2008:2(2) 384
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intravitreal injection of multiple doses VEGF trap (0.05, 
0.15, 0.5, 1, 2, and 4 mg). At 6 weeks, mean gain in visual 
acuity was 4.8 letters and mean OCT central retinal thickness 
decreased from 298 to 208 μm (Nguyen et al 2006). The 
potential beneﬁ  t of VEGF trap is a sustained effect compared 
to single injections of other VEGF-binding agents, although 
this has not been demonstrated in a head-to-head trial. A 
phase II VEGF trap study (CLEAR-AMD) is currently in 
the process of enrolling patients.
Small interfering RNA
The 2006 Nobel Prize in Physiology or Medicine was 
awarded to Andrew Fire and Craig Mello for their work in 
RNA interference, the process by which small interfering 
RNA (siRNA) molecules inactivate messenger RNA, thereby 
suppressing RNA translation. For clinical use, these drugs 
are administered as double-stranded RNA molecules that 
are imported across the cellular membrane and processed 
by an enzyme, Dicer, which shortens the siRNA to 21–24 
nucleotides. The processed siRNA is incorporated into a 
RNA-induced silencing complex (RISC), which, when 
activated, binds complementary mRNA and digests it. This 
allows a single molecule of siRNA to degrade multiple 
copies of mRNA.
The ﬁ  rst drug to employ this mechanism in the treatment 
of neovascular AMD is bevasiranib (formerly Cand5, Acuity 
Pharmaceuticals, Philadelphia, PA) and is targeted against 
VEGF mRNA. The Cand5 Anti-VEGF RNA Evaluation 
(CARE) study was a phase II study of 3 doses of bevasiranib 
(0.2, 1.5, and 3.0 mg) injected intravitreally 6 weeks apart 
(n = 127 eyes). At 12 weeks after the initial injection, mean 
loss of vision was 4.1 letters (0.2 mg dose), 6.9 letters (1.5 mg 
dose), or 5.8 letters (3.0 mg dose), with 71.8–79.4% losing 
less than 3 lines. Adverse events included stroke (0.8%), 
arrhythmia (0.8%), and hypertension (5.5%) (Tolentino 
2006). Compared to improvement in vision seen with other 
therapies, including ranibizumab, bevacizumab, and VEGF 
trap, the vision loss in these patients does not bode well for the 
use of bevasiranib as monotherapy. By targeting a relatively 
upstream component of the VEGF pathway, it is currently 
considered that the use of siRNA may have a delayed effect 
in inﬂ  uencing disease processes. The recent FDA approval 
of ranibizumab may prompt a design change in the phase III 
study of bevasiranib to include injection of a VEGF-binding 
agent at baseline. The combination of VEGF binding by 
ranibizumab or bevacizumab combined with the mRNA 
interference of bevasiranib has the theoretic advantage 
of preventing further vision deterioration by immediately 
binding existent VEGF while interfering with the upstream 
production of VEGF.
A second siRNA drug, sirna-027 (Sirna Therapeutics, 
San Francisco, CA), directed against VEGF receptor 1 
(VEGFR1), has demonstrated efﬁ  cacy in animal models 
(Shen et al 2006) and reasonable safety in a Phase I trial and 
is undergoing phase II evaluation currently.
VEGF receptor tyrosine
kinase inhibition
A further method of inhibiting the effect of increased 
VEGF within the eye with CNV is to inhibit the tyrosine 
kinase activity of VEGF receptors. Vatalanib® (formerly 
PTK-787, Novartis International AG, Basel, Switzerland) 
is a potent inhibitor of all known VEGF receptor tyrosine 
kinases, VEGFR1 (sFlt-1), VEGFR2 (KDR), and VEGFR3 
(Flt-4). The use of vatalanib is an attractive alternative to 
intravitreally or intravenously injected medications because 
of its satisfactory oral bioavailability. Preclinical data have 
demonstrated inhibition of experimental retinal and choroidal 
neovascularisation (Maier et al 2005). Clinical studies in 
healthy individuals have shown no serious adverse events and 
adverse events from the use of vatalanib in patients with solid 
and hematologic malignancies have included nausea/vomiting, 
fatigue, dizziness, diarrhoea, and hypertension (Joondeph et al 
2006). The Study of Vatalanib and Photodynamic Therapy 
with Verteporfin in Patients With Subfoveal Choroidal 
Neovascularization (CNV) Secondary to Age-related Macular 
degeneration (ADVANCE) is currently enrolling for a phase 
I/II comparison of PDT to PDT/vatalanib.
PEDF
Pigment epithelial-derived growth factor (PEDF) is 
a factor with neurotrophic, neuroprotective, and anti-
angiogenic properties (Steele et al 1993; Mori et al 2002). 
The potential beneﬁ  t of PEDF in preventing damage due 
to neovascular AMD lies in its multifaceted protection of 
the retina and retinal pigment epithelium and inhibition 
of angiogenesis. CDNA encoding human PEDF has 
been shown to inhibit ocular neovascularization when 
introduced into the vitreous and subretinal space of 
animal models via an adenoviral vector (AdPEDF.11, 
GenVec, Inc., Gaithersburg, MD, USA) (Imai et al 
2005). A phase I study of AdPEDF.11 in 28 patients 
demonstrated no dose-limiting toxicity and suggested that 
its anti-angiogenic effect lasts for months (Campochiaro 
et al 2006). Furthermore, therapy does not seem to be 
associated with a systemic immune response, thereby Clinical Ophthalmology 2008:2(2) 385
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theoretically allowing for repeat injections (Hamilton 
et al 2006). The sustained effect and repeatability of this 
therapy is attractive approach given the relatively short 
duration of anti-VEGF agents.
Squalamine lactate
Squalamine lactate (Evizon®, Genaera Corporation, Plymouth 
Meeting, PA) is an anti-angiogenic amino sterol derived 
from cartilage of the dogﬁ  sh shark, Squalus acanthus. Its 
mechanism of action includes blockade of cell membrane 
ion transporters that regulate cell function by controlling pH 
and metabolism. When bound to calmodulin, squalamine 
also blocks the action of VEGF and integrin expression, 
thereby inhibiting angiogenesis. Squalamine is ineffective 
when administered intravitreally and therefore requires 
intravenous dosing. However, systemic dosing has yielded 
promising results in rats (Ciulla et al 2003) as well as humans 
(Kaiser 2007). In a phase I/II clinical trial of 40 patients 
who had received 25 or 50 mg/m2 weekly for 4 weeks, no 
patients lost vision and 26% gained 3 or more lines. Genaera 
has abandoned this product and is no longer in clinical 
development.
Anecortave acetate
Anecortave acetate has also been used in patients with 
AMD-related CNV. In these patients, Anecortave acetate 
produced similar visual acuity results to PDT with 
verteporﬁ  n in the C-01-99 study (Slakter et al 2006). With 
improved therapies and outcomes, anecortave acetate is 
not appropriate monotherapy for active CNV. However, 
the NEI is sponsoring the BRIDGE study that will 
evaluate combination therapy of anecortave acetate and 
ranibizumab.
Vitreoretinal surgery
The suggestion that surgical removal of CNV before 
the development of subretinal ﬁ  brosis would allow for 
reapposition of healthy RPE and photoreceptors, thereby 
improving visual acuity is an attractive one. Multiple 
techniques and modiﬁ  cations have been tried to improve 
visual acuity outcomes in patients with CNV, including 
submacular surgical removal of CNV (Hawkins et al 2004), 
pneumatic displacement of large subretinal haemorrhage 
(Hassan et al 1998), and macular translocation (deJuan et al 
1998; Mruthyunjaya et al 2004). To date, none of these 
therapies has proven effective, and with rare exception, 
none are appropriate primary treatment strategies for AMD-
associated CNV.
Combination therapy
As with many therapies, which have been borrowed from 
oncology for use in the treatment of neovascular AMD, the 
concept of “induction and maintenance” is one employed in 
several combined management approaches in an effort to 
improve therapeutic efﬁ  cacy and reduce treatment frequency. 
As indicated previously, PDT has been implicated in having 
the undesirable observation of increasing inﬂ  ammation and 
VEGF levels (Schmidt-Erfurth et al 2003). By combining 
treatment modalities, an opportunity exists to reﬁ  ne the 
blockade of angiogenesis and vascular permeability. For 
example combination of PDT, intravitreal anti-VEGF 
agent and steroid could in theory allow for blockade of 
CNV at multiple levels. The FOCUS study is a phase I/II 
trial comparing as-needed dosing of verteporﬁ  n followed 
by monthly dosing of either ranibizumab or sham injection. 
At 2 years, the ranibizumab/PDT group gained a mean 
of 4.6 letters whereas the sham/PDT group lost a mean 
of 7.8 letters. The number of treatments through 2 years 
averaged 1.4 in the ranibizumab/PDT group compared to 
4.0 in the sham/PDT group (Heier, Antoszyk, et al 2006; 
Heier, Boyer, et al 2006).
In a prospective, non-comparative, interventional 
case series, 104 patients underwent triple therapy using 
intravitreal dexamethasone (800 μg) and bevacizumab 
(1.5 mg) administered within a mean of 16 hours after PDT 
(Agustin et al 2007). All 104 patients received one triple 
therapy cycle while 5 patients received a second triple 
treatment due to remaining CNV activity. The triple therapy 
was complemented in 18 patients (17.3%) by an additional 
intravitreal injection of bevacizumab. The mean follow-up 
period was 40 weeks (range, 22–60 weeks). Mean increase 
in visual acuity was 1.8 lines (p   0.01). Mean decrease in 
retinal thickness was 182 micrometers (p   0.01). No serious 
adverse events were observed. The authors concluded that 
triple therapy results in signiﬁ  cant and sustained visual acuity 
improvement after only one cycle of treatment in patients 
with AMD associated CNV. In addition, the therapy offered 
a good safety proﬁ  le and potentially lower cost compared 
with therapies that must be administered more frequently, 
and convenience for patients (Agustin et al 2007). The 
PDT was performed with a reduced time of light delivery 
(70 seconds) in an effort to theoretically reduce choroidal 
damage (Michels et al 2006).
The Neovascular Age-related macular degeneration, 
Periocular corticosteroids and Photodynamic therapy 
(NAPP) trial evaluated 67 patients with AMD and subfoveal 
CNV. Thirty-four patients were given a single periocular Clinical Ophthalmology 2008:2(2) 386
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injection of corticosteroid, followed immediately by PDT 
with verteporﬁ  n, and 33 patients were given PDT alone. No 
difference in visual acuity or angiographic leakage between 
the groups was observed at 6 months (NAPP Trial Research 
Group et al 2007).
Several other studies are combining therapeutic 
modalities, including the BRIDGE study (ranibizumab plus 
anecortave acetate), PROTECT study (ranibizumab plus PDT 
with verteporﬁ  n), VISION phase IV study (pegaptanib plus 
PDT) are currently underway.
Future directions
Another target of angiogenesis has been through non-
VEGF pathways, including bioactive lipids. Sphingomab 
(Lpath Inc., San Diego, CA) is a monoclonal antibody 
targeted against sphingosine-1-phosphate, which has been 
implicated in angiogenesis, scar formation, and inﬂ  ammation 
(Sabbadine 2006). Studies have been very preliminary, 
but the reminder that VEGF is not the only contributor to 
angiogenesis is important, and may play a further role in 
combination therapy.
Encapsulated Cell Technology (ECT), developed by 
Neurotech, Lincoln, RI, involves implantation into the 
vitreous cavity of a small semi-permeable polymer capsule. 
The capsular implant is lined with cultured cells that have 
been engineered to secrete certain proteins or peptides. The 
initial studies of ECT in humans have been phase I trials of 
ECT containing modiﬁ  ed human retinal pigment epithelial 
cells (ARPE-19), programmed to secrete ciliary neurotrophic 
factor (CNTF) in the treatment of retinitis pigmentosa and 
non-neovascular AMD (Tao et al 2002; Sieving et al 2006). 
Assuming that these capsules demonstrate immune privilege, 
ECT allows for theoretically sustained low-dose delivery of 
a single or combination of proteins or other cellular products 
into the vitreous cavity.
Rather than replacing specific defective genes or 
supplying deﬁ  cient proteins, some have advocated replacing 
entire cell lines and tissues. Although not yet ready for human 
trials, stem cell transplantation and retinal pigment epithelium 
transplantation are enticing goals for the management of 
chronic blinding diseases (Francis et al 2003). Signiﬁ  cant 
challenges with these therapeutic modalities include 
identifying pluripotent cells, controlling their differentiation 
and understanding the relationships between modiﬁ  ed cells 
and the immune system.
Recent advances in the understanding of the relationship 
between genetic susceptibility and AMD have raised new 
questions regarding the influence of immunity on the 
occurrence of CNV. One example of this is the recent 
association between complement factor H haplotypes and 
AMD (Edwards et al 2005). Further understanding will 
allow for genetic testing and identiﬁ  cation of individuals 
at high risk for CNV and those appropriate for intensive 
prophylactic therapies.
Conclusion
In the last 3 years, the tertiary intervention for AMD-related 
CNV, the leading cause of irreversible severe vision loss in 
AMD, has shifted from a predominantly laser based treatment 
approach to a more targeted pharmacotherapeutic approach. 
We have determined that pharmacotherapy is superior to laser 
based treatment in many patients with AMD-related CNV, 
allowing for better outcomes in visual acuity and retinal 
anatomy and has made treatment available to neovascular 
AMD patients who were previously poor candidates for 
laser-based therapy.
In this time, we have learned also that non-selective 
VEGF blockade by agents like ranibizumab and bevacizumab 
appears more efﬁ  cacious in the short-term treatment of AMD-
associated CNV than the use of selective VEGF blockade 
by agents like pegaptanib. At this juncture, caution still 
needs to be exercised, as the long-term risks of non-selective 
VEGF blockade are entirely unknown. Given the potential 
neuroprotective role of VEGF, in theory, complete and 
sustained VEGF blockade might result in long-term vision 
loss in AMD-related CNV.
The use of pharmacologic agents as monotherapy has 
allowed patients to recover vision faster than with previous 
treatment modalities but the effects are frequently, but 
not always, short-lived. A sustained beneficial effect 
has only been shown in treatment schedules requiring 
frequent intravitreal injections. As our understanding of 
the pathophysiologic mechanism of angiogenesis and the 
pharmacodynamics of anti-angiogenic agents improve, we 
have the opportunity to reﬁ  ne our treatment approach. The use 
of combination therapy, involving manipulation of multiple 
aspects of the angiogenesis cascade, is being investigated 
in patients with AMD-related CNV. Providing rapid and 
sustained improvement in the vision and function while 
reducing the risks and treatment burden of administering 
pharmaco-monotherapy may be the way of the very near 
future. While pharmacotherapy has help tremendously in 
the care of these patients with VEGF-mediated disease, 
long-term goals in the management of AMD will also need 
to address other sequelae such as vision-limiting macular 
ischemia, atrophy, and subretinal ﬁ  brosis in those patients Clinical Ophthalmology 2008:2(2) 387
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with disease non-responsive to anti-VEGF agents or those 
patients with inactive but advanced disease. In addition, 
further investigations aimed at preventing the progression 
of both the neovascular and non-neovascular forms of the 
disease prior to the onset of vision loss will be instrumental 
in affording patients to maintain a better quality of life in 
this period of increasing life expectancy.
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